ctDNA at Baseline Linked With Larger Tumor Size and Residual Cancer Burden
In a presentation at the 2024 San Antonio Breast Cancer Symposium (SABCS), data from the phase 2 PELOPS investigational trial (NCT02764541) was shared that showed, in patients with primary hormone receptor (HR)–positive early breast cancer, ultra-sensitive …